WISP2 Antibody, HRP conjugated

1. The authors show that, in triple-negative-breast cancer (TNBC) cells enriched with tumor initiating cells, CCN5 significantly blocks cellular growth via apoptosis, reversing epithelial-mesenchymal-transition-signaling and impairing mammosphere formation, thereby blocking the tumor-forming ability and invasive capacity of these cells. PMID: 28450698
2. by analyzing different estrogen receptor-alpha(ER-a)-positive and ER-a-negative breast cancer cell lines, we defined the role of CCN5 in the leptin-mediated regulation of growth and invasive capacity. PMID: 29370782
3. CCN3 (Nov) and CCN5 (WISP2) are novel substrates of MMP14. PMID: 27471094
4. Results show that WISP2 and beta-catenin were more highly expressed in gastric cancer tissues and seem to correlate with early stage or without metastasis. PMID: 28739741
5. Report opposing effects of CCN2 and CCN5 on fibroblast proliferation and transdifferentiation induced by TGF-beta. PMID: 26218313
6. Serum WISP2 correlated directly with fatty acid binding protein 4. Serum SFRP5 did not differ between obese (n=32) vs. nonobese (n=25) PCOS women, but reference women had lower SFRP5 (p<5x10(-6) as compared to both PCOS groups). PMID: 25089371
7. Activation of CCN5 may have the therapeutic potential to kill triple-negative breast cancer. PMID: 25132260
8. WISP2 has a role in regulating tumor cell susceptibility through EMT by inducing the TGF-beta signaling pathway, KLF-4 expression and miR-7 inhibition. PMID: 24931170
9. The obtained results indicate that the changes in gene expression in bone marrow progenitor cells can be involved into space flight-induced osteopenia. PMID: 25509878
10. overexpression of FGFBP1 or loss of WISP-2 expression is closely related to the metastasis, invasion and poor prognosis of gallbladder cancer. PMID: 23592278
11. Loss of WISP2 in estrogen-dependent MCF7 human breast cancer cells promotes a stem-like cell phenotype. PMID: 24498388
12. We demonstrate that the overexpression of CCN5 in lung fibroblasts suppresses the upregulation in the expression of alpha-SMA and collagen induced by CCN2. PMID: 24276150
13. WISP2 exerts dual actions in mesenchymal precursor cells; secreted WISP2 activates canonical WNT and maintains the cells in an undifferentiated state, whereas cytosolic WISP2 regulates adipogenic commitment. PMID: 24451367
14. Regulation of invasion by WISP2 may involve the WNT signalling pathway. PMID: 23893926
15. WISP2 regulates preadipocyte commitment and PPARgamma activation by BMP4. PMID: 23359679
16. WISP2 gene expression is regulated both by obesity and by the region between visceral and subcutaneous adipose tissue. PMID: 22616691
17. Studies suggest a novel regulatory pathway exists through which CCN5 exerts its anti-invasive function. PMID: 22020939
18. CCN5 represses expression of genes associated with epithelial-mesenchymal transition (EMT) as well as expression of key components of the transforming growth factor beta (TGF-beta) signaling pathway. PMID: 21262769
19. The CCN5/WISP2 were downregulated in paired comparisons of plexiform neurofibroma and malignant peripheral nerve sheath tumor. PMID: 20010302
20. Overexpression of WISP2 is associated with breast cancer PMID: 11855747
21. disruption of WISP-2 signaling by use of antisense oligomers caused a significant reduction in breast tumor cell proliferation PMID: 12659671
22. WISP2 was overexpressed in gastrointestinal peptide-independent ACTH-independent macronodular adrenal hyperplasia. PMID: 14767469
23. regulation of phosphorylation of ER-alpha and EGFR may play critical roles in EGF-induced transcriptional activation of WISP-2 gene in breast tumor cells PMID: 15798095
24. These data demonstrate that the expression of WISP2 is synergistically upregulated in RA synovial fibroblasts by estrogen and WNT pathways, and suggest an involvement in the pathology of the disease. PMID: 16038875
25. Results suggest that WISP-2 could be a reliable independent marker and that down-regulation or loss of the WISP-2 gene may be associated with the development of salivary gland tumors. PMID: 16525711
26. WISP-2/CCN5 is a novel signaling molecule that critically participates in the mitogenic action of PMA on noninvasive, WISP-2/CCN5-positive breast tumor cells through PKCalpha-dependent, multiple molecular signal transduction pathways. PMID: 16939222
27. Data suggest WISP-2/CCN5 silencing may be a critical event during differentiation and progression of pancreatic adenocarcinoma. PMID: 17383817
28. WISP-2 had greater levels of expression in node-positive tumors; higher levels in both moderate and poor prognostic groups compared with the good prognostic group; greater level in both grade 2 and 3 when compared with grade 1. PMID: 17406949
29. WISP-2/CCN5 is an important regulator involved in the maintenance of a differentiated phenotype in breast tumor epithelial cells and may play a role in tumor cell invasion and metastasis PMID: 18070926
30. Loss of CCN5 is associated with gain of oncogenic function of p53 mutants invasiveness in breast cancer PMID: 18559502
31. CCN5 mRNA and protein level was almost undetectable in poorly differentiated breast cancers compared with the moderately or well-differentiated samples and its expression inversely correlated with lymph node positivity. PMID: 18794149

Show More

Hide All

HGNC: 12770

OMIM: 603399

KEGG: hsa:8839

STRING: 9606.ENSP00000190983

UniGene: Hs.592145